HIV-1 viral decay in blood and semen in antiretroviral-naive adults initiating dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide

被引：0
|
作者：
Wang, Ran [1 ]
Liu, Yongjian [2 ]
Sun, Lijun [1 ]
Li, Aixin [1 ]
Lv, Shiyun [1 ]
Zhai, Yuanyi [1 ]
Li, Rui [1 ]
Hua, Wei [1 ]
Wang, Xi [1 ]
Li, Lin [2 ]
Dai, Lilli [1 ]
机构：
[1] Capital Med Univ, Beijing Youan Hosp, Ctr Infect Dis, Beijing, Peoples R China
[2] Acad Mil Med Sci, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2024年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P114
引用
收藏
页码：121 / 121
页数：1
相关论文
共 50 条
  • [41] Assessing the effectiveness and safety of lamivudine/dolutegravir versus bictegravir/emtricitabine/tenofovir alafenamide fumarate in adults living with human immunodeficiency virus: One retrospective observational cohort study
    Cheng, C. -Y.
    Ku, S. -Y.
    Hsieh, H. -T.
    Lin, M. -H.
    Chang, S. -Y.
    Sun, N. -L.
    Lin, Y. -C.
    Chen, C. -P.
    Cheng, S. -H.
    HIV MEDICINE, 2023, 24 : 146 - 147
  • [42] Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1
    Stella-Ascariz, Natalia
    Montejano, Rocio
    Rodriguez-Centeno, Javier
    Alejos, Belen
    Schwimmer, Christine
    Bernardino, Jose I.
    Rodes, Berta
    Allavena, Clotilde
    Hoffmann, Christian
    Gisslen, Magnus
    de Miguel, Rosa
    Esteban-Cantos, Andres
    Wallet, Cedrick
    Raffi, Francois
    Arribas, Jose R.
    JOURNAL OF INFECTIOUS DISEASES, 2018, 218 (10): : 1523 - 1530
  • [43] Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China
    Cao Jing
    Tang Wei
    Wang Ning
    Zheng Fang
    Xiao Gang
    Wang Xingzhi
    Zhou Guoqiang
    Wang Min
    BMC Infectious Diseases, 23
  • [44] Bictegravir-based antiretroviral therapy in HIV-1 group O patients: data from real-life bictegravir/emtricitabine/tenofovir alafenamide switches
    Martin, Charlene
    Unal, Guillemette
    Plantier, Jean-Christophe
    Alessandri-Gradt, Elodie
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (08) : 2305 - 2307
  • [45] Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection (vol 78, pg 1817, 2018)
    Deeks, Emma D.
    DRUGS, 2019, 79 (06) : 687 - 687
  • [46] Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Late-Presenting People With HIV-1 Infection
    Yang, Xiaoyan
    Xie, Xiaoxin
    Fu, Yanhua
    Gan, Lin
    Ma, Shujing
    Long, Hai
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (11):
  • [47] Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults
    Goodgame, JC
    Pottage, JC
    Jablonowski, H
    Hardy, WD
    Stein, A
    Fischl, M
    Morrow, P
    Feinberg, J
    Brothers, CH
    Vafidis, I
    Nacci, P
    Yeo, J
    Pedneault, L
    ANTIVIRAL THERAPY, 2000, 5 (03) : 215 - 225
  • [48] Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naive Adults With HIV-1 Infection
    Santevecchi, Barbara A.
    Miller, Stacy
    Childs-Kean, Lindsey M.
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (12) : 1252 - 1259
  • [49] Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
    Sax, Paul E.
    Pozniak, Anton
    Montes, M. Luisa
    Koenig, Ellen
    DeJesus, Edwin
    Stellbrink, Hans-Juergen
    Antinori, Andrea
    Workowski, Kimberly
    Slim, Jihad
    Reynes, Jacques
    Garner, Will
    Custodio, Joseph
    White, Kirsten
    SenGupta, Devi
    Cheng, Andrew
    Quirk, Erin
    LANCET, 2017, 390 (10107): : 2073 - 2082
  • [50] Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
    Stellbrink, Hans-Juergen
    Arribas, Jose R.
    Stephens, Jeffrey L.
    Albrecht, Helmut
    Sax, Paul E.
    Maggiolo, Franco
    Creticos, Catherine
    Martorell, Claudia T.
    Wei, Xuelian
    Acosta, Rima
    Collins, Sean E.
    Brainard, Diana
    Martin, Hal
    LANCET HIV, 2019, 6 (06): : E364 - E372
12345